1.1 Brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone (CHP) is recommended, within its marketing authorisation, as an option for untreated systemic anaplastic large cell lymphoma in adults. It is only recommended if the company provides brentuximab vedotin according to the commercial arrangement.
Why the committee made these recommendations
Standard care for untreated systemic anaplastic large cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).
Clinical evidence shows that people with systemic anaplastic large cell lymphoma who have brentuximab vedotin with CHP live longer and have longer before their disease progresses than people who have CHOP.
There is uncertainty about the modelling, but the most likely cost-effectiveness estimate is within what NICE considers an acceptable use of NHS resources. Therefore, brentuximab vedotin with CHP is recommended.